Clinical trial
A Study of Intravenous INO-1001 Plus Oral Temozolomide to Evaluate Tolerability…
NCT00272415 · Genentech, Inc., Industry · Terminated
Key facts
| NCT number | NCT00272415 |
|---|---|
| Title | A Study of Intravenous INO-1001 Plus Oral Temozolomide to Evaluate Tolerability, Safety, and Pharmacokinetics in Patients With Melanoma |
| Official title | A Phase Ib, Open-Label, Multicenter Trial of Intravenous INO-1001 Plus Oral Temozolomide to Evaluate the Tolerability, Safety, and Pharmacokinetics in Subjects With Newly-Diagnosed or Recurrent Unresectable Stage III or Stage IV Melanoma |
| Lead sponsor | Genentech, Inc., Industry |
| Status | Terminated |
| Phase | Phase 1 |
| Study type | Interventional |
| Conditions | Melanoma |
| Intervention type | Drug |
| Interventions | INO-1001, temozolomide |
| Enrollment | 39 |
| Start date | Oct 1, 2005 |
| First posted | Jan 6, 2006 |
| Last update posted | Mar 11, 2009 |
At a glance
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: